Entropy Neurodynamics (ASX:ENP) is a clinical-stage biotechnology company focused on developing psychedelic-based therapies, particularly using psilocin (the active metabolite of psilocybin).
Island (ASX:ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.
Racura Oncology (ASX:RAC) is an ASX-listed Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small-molecule anticancer agent that inhibits the cancer growth regulator MYC through G4-DNA & RNA binding.
Rize Oncology Inc. is a clinical-stage biopharmaceutical company dedicated to the development of STS-201, a small-molecule drug with a unique mechanism of action, currently being evaluated for treating soft tissue sarcoma and other cancers.